Selection of 1.2 mg/kg dose of ALRN-6924 with the goal to extend duration of cell cycle arrest and, thus, chemoprotection New primary endpoint that is more closely aligned with regulatory precedents ...

Whatever its credentials as a sports car—and they seem to be impressive—the Spyker C8 Aileron is an attention-getting device of pretty intense wattage. It even draws stares from the pilots of Ferraris ...

Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. Now, the biotech has distanced itself from its premerger form by rebranding ...

Spyker Cars, manufacturer of premium sport cars, unveiled its second generation C-line sports car at the Salon International de l’Auto in Geneva, Switzerland today: The all aluminium Long Wheel Base ...

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to ...

AUSTIN, Texas, July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF ...

Spyker Cars may not have impressed in its F1 venture, but it certainly has made up for it off the track. The exclusive sportscar-maker has kept true to its promise made in March at the Geneva Auto ...

Aileron Therapeutics' Phase 1b trial of inhaled LTI-03 showed positive trends in seven out of eight IPF biomarkers. LTI-03 reduced SPD by 5% at 14 days, outperforming current IPF standard care's 4% ...